MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-23-2026
Theravance Biopharma Net Debt 2011-2026 | TBPH
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Theravance Biopharma
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -125 M | 12 M | 9.61 M | -246 M | 527 M | - | 397 M | 76.3 M | 135 M | -122 M | -113 M | -89.2 M | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 527 M | -246 M | 42 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Biotechnology industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Applied Genetic Technologies Corporation
AGTC
|
-36 M | - | - | $ 26.5 M |  USA |
 |
MorphoSys AG
MOR
|
163 M | - | 2.43 % | $ 254 M |  Germany |
 |
Allakos
ALLK
|
-25 M | - | - | $ 28.6 M | USA |
 |
Advaxis
ADXS
|
3.42 M | - | -9.65 % | $ 45.9 M | USA |
 |
Akouos
AKUS
|
-92.9 M | - | 0.23 % | $ 488 M | USA |
 |
AlloVir
ALVR
|
-62.7 M | - | 4.14 % | $ 49.1 M | USA |
 |
Compugen Ltd.
CGEN
|
-5.05 M | $ 2.56 | -6.41 % | $ 239 M |  Israel |
 |
I-Mab
IMAB
|
-1.06 B | - | - | $ 866 M |  China |
 |
Aeglea BioTherapeutics
AGLE
|
-30.2 M | - | - | $ 1.01 B | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-12 M | - | -11.43 % | $ 502 K | USA |
 |
Midatech Pharma plc
MTP
|
-6.17 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
-402 M | - | - | $ 40.3 B | USA |
 |
Aptorum Group Limited
APM
|
-2.77 M | $ 0.89 | 1.48 % | $ 6.54 M | China |
 |
Biophytis SA
BPTS
|
-4.01 M | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
2.27 M | - | 2.54 % | $ 160 B | France |
 |
ACADIA Pharmaceuticals
ACAD
|
-83 M | $ 22.24 | -1.9 % | $ 3.69 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-824 K | - | -1.52 % | $ 24.7 M | USA |
 |
Evogene Ltd.
EVGN
|
-3.44 M | $ 0.79 | -0.65 % | $ 27.9 M | Israel |
 |
Fennec Pharmaceuticals
FENC
|
17.7 M | $ 6.15 | -8.21 % | $ 176 M | USA |
 |
Applied Molecular Transport
AMTI
|
-56.5 M | - | - | $ 10.1 M | USA |
 |
AIkido Pharma
AIKI
|
-31.2 M | - | 1.93 % | $ 17.4 M | USA |
 |
Galapagos NV
GLPG
|
-1.29 B | $ 27.84 | -2.04 % | $ 2.69 B |  Belgium |
 |
Applied Therapeutics
APLT
|
-49.4 M | - | - | $ 8.42 M | USA |
 |
Aptinyx
APTX
|
-33.8 M | - | -39.0 % | $ 4.57 M | USA |
 |
ImmuCell Corporation
ICCC
|
3.77 M | $ 8.42 | 0.88 % | $ 76 M | USA |
 |
Avenue Therapeutics
ATXI
|
-3.13 K | - | -52.27 % | $ 4.45 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
246 M | - | - | - |  Russia |
 |
Aeterna Zentaris
AEZS
|
-65.1 M | - | 5.93 % | $ 314 M |  Canada |
 |
Innoviva
INVA
|
-293 M | $ 23.07 | -2.62 % | $ 1.55 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-657 K | - | - | $ 7.46 M | Israel |
 |
AgeX Therapeutics
AGE
|
12.6 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aravive
ARAV
|
-49.6 M | - | -13.39 % | $ 1.45 M | USA |
 |
Innate Pharma S.A.
IPHA
|
-120 M | $ 1.49 | 6.33 % | $ 235 M | France |
 |
Aridis Pharmaceuticals
ARDS
|
-3.05 M | - | 17.91 % | $ 11.1 M | USA |
 |
Atreca
BCEL
|
33.1 M | - | -11.76 % | $ 5.79 M | USA |
 |
BioNTech SE
BNTX
|
-973 M | $ 100.23 | -1.8 % | $ 27.2 B | Germany |
 |
Brainstorm Cell Therapeutics
BCLI
|
533 K | - | -2.5 % | $ 5.88 M | USA |
 |
BioDelivery Sciences International
BDSI
|
-33.1 M | - | -4.8 % | $ 255 M | USA |
 |
Jaguar Health
JAGX
|
116 K | $ 0.23 | -5.81 % | $ 536 K | USA |
 |
Inventiva S.A.
IVA
|
-95.6 M | $ 4.91 | -2.0 % | $ 138 M | France |
 |
Aquestive Therapeutics
AQST
|
-75.5 M | $ 4.04 | -1.34 % | $ 432 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
65.3 M | $ 22.36 | -3.99 % | $ 2.84 B | USA |
 |
KalVista Pharmaceuticals
KALV
|
-55.5 M | $ 26.71 | 38.8 % | $ 1.44 B | Britain |
 |
Kamada Ltd.
KMDA
|
-70.2 M | $ 8.15 | - | $ 260 M | Israel |
 |
Autolus Therapeutics plc
AUTL
|
-32.7 M | $ 1.42 | -4.39 % | $ 378 M | Britain |
 |
Aptose Biosciences
APTO
|
-5.53 M | - | -45.71 % | $ 1.2 M | Canada |
 |
AstraZeneca PLC
AZN
|
9.86 B | - | - | $ 96.9 B | Britain |
 |
AVROBIO
AVRO
|
-76.6 M | - | 1083.1 % | $ 745 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-3.5 M | $ 2.95 | 1.2 % | $ 4.86 M | Israel |
 |
BeiGene, Ltd.
BGNE
|
-3.56 B | - | 0.49 % | $ 251 B |  Cayman-islands |